Envista (NYSE:NVST) PT Lowered to $23.00 at JPMorgan Chase & Co.

Envista (NYSE:NVST) had its price target cut by JPMorgan Chase & Co. from $29.00 to $23.00 in a research report report published on Thursday, Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms have also recently commented on NVST. Jefferies Financial Group cut Envista from a buy rating to a hold rating and dropped their price objective for the stock from $30.00 to $23.00 in a research report on Friday, February 9th. Morgan Stanley downgraded shares of Envista from an overweight rating to an equal weight rating and reduced their price objective for the company from $33.00 to $21.00 in a research note on Friday, April 26th. SVB Leerink began coverage on Envista in a report on Monday, February 26th. They issued an underperform rating and a $19.00 price target for the company. William Blair downgraded Envista from an outperform rating to a market perform rating in a research report on Thursday, February 8th. Finally, Leerink Partnrs reiterated an underperform rating on shares of Envista in a research note on Monday, February 26th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $25.86.

Envista Price Performance

Envista stock opened at $19.00 on Thursday. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 0.34. The firm’s 50-day simple moving average is $20.66 and its 200 day simple moving average is $22.50. Envista has a 52 week low of $18.09 and a 52 week high of $36.74. The firm has a market capitalization of $3.27 billion, a PE ratio of -26.39, a P/E/G ratio of 3.68 and a beta of 1.35.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). The business had revenue of $623.60 million for the quarter, compared to analysts’ expectations of $634.85 million. Envista had a positive return on equity of 5.84% and a negative net margin of 4.70%. The company’s revenue for the quarter was down .6% on a year-over-year basis. During the same period last year, the business earned $0.38 earnings per share. On average, equities research analysts predict that Envista will post 1.26 EPS for the current fiscal year.

Institutional Trading of Envista

A number of institutional investors have recently added to or reduced their stakes in NVST. Vanguard Group Inc. lifted its stake in shares of Envista by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 17,167,767 shares of the company’s stock worth $413,056,000 after purchasing an additional 944,596 shares in the last quarter. Ariel Investments LLC grew its stake in shares of Envista by 4.3% during the third quarter. Ariel Investments LLC now owns 5,335,578 shares of the company’s stock valued at $148,756,000 after acquiring an additional 218,461 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Envista by 65.3% during the fourth quarter. Franklin Resources Inc. now owns 5,262,092 shares of the company’s stock worth $126,606,000 after acquiring an additional 2,077,786 shares during the last quarter. Nuance Investments LLC boosted its holdings in Envista by 953.8% in the fourth quarter. Nuance Investments LLC now owns 3,931,054 shares of the company’s stock valued at $94,581,000 after purchasing an additional 3,558,031 shares during the last quarter. Finally, River Road Asset Management LLC acquired a new stake in Envista during the 4th quarter valued at approximately $54,931,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.